Therapeutics and Clinical Risk Management最新文献

{"title":"Clinical and Radiological Factors Associated with Nonoperative Management Failure for Small Bowel Obstruction: A Retrospective Study from a Resource-Limited Setting.","authors":"Saleh Al-Wageeh, Qasem Alyhari, Faisal Ahmed, Hanan Mohammed, Noha Dahan, Abdullatif Mothanna Almohtadi, Sameer Taha Said Al-Nuzili, Mohamed Badheeb, Abdulsattar Naji","doi":"10.2147/TCRM.S496629","DOIUrl":"10.2147/TCRM.S496629","url":null,"abstract":"<p><strong>Background: </strong>Recognizing factors that predict non-operative management (NOM) failure for patients with small bowel obstruction (SBO) aids in limiting surgical intervention when needed. This study investigated the predictive factors for NOM failure in SBO patients in a resource-limited setting.</p><p><strong>Material and method: </strong>A retrospective study included 165 patients who were diagnosed with SBO and were admitted and managed at Althora General Hospital, IBB, Yemen, from April 2022 to March 2024. Patients' baseline characteristics and profiles along with factors associated with failure of NOM were investigated and analyzed with univariate and multivariate analysis.</p><p><strong>Results: </strong>51 (30.4%) of included cohorts were managed non-operatively. The mean age was 47.7±16.9 years, and males were disproportionally presented (62.7%). The majority of patients presented with abdominal pain (96.1%). Failure of NOM was seen in 18 (35.3%) patients and intra-operative findings were adhesive bands, volvulus, intussusception, and mesenteric ischemia in 7 (38.9%), 5 (27.8%), 4 (22.2%), and 2 (11.1%) patients, respectively. Bowel resection was performed in 11 (61.1%), and 4 of them needed a colostomy diversion. Postoperative complications occurred in 13 (25.5%) patients, including fever, paralytic ileus, surgical site infection, and reoperation in 13 (25.5%), 5 (9.8%), 4 (7.8%), and 2 (3.9%) patients, respectively. Sixteen patients were discharged, and two patients died due to mesenteric ischemia. Among NOM successful patients, recurrence has occurred in 8 patients. In multivariate analysis, poor bowel wall enhancement (OR: 8.59; 95% CI: 1.14-64.59, p=0.037) and high level of obstruction (OR: 11.64; 95% CI: 1.34-100.85, p=0.026) in computed tomography (CT) scan were independently associated with NOM failure.</p><p><strong>Conclusion: </strong>Poor bowel wall enhancement and significant obstruction on CT images are critical indicators for selecting SBO patients requiring urgent surgery. However, evaluating the advantages of surgical intervention versus NOM demands a comprehensive analysis of surgical risks, comorbidities, and the presence of bowel strangulation or ischemia.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"893-906"},"PeriodicalIF":2.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Bleeding Related Events in Robotic-Assisted Partial Nephrectomy for Angiomyolipoma: Simplifying Risk Assessment with Tumor Diameter and Depth, A Retrospective Study.","authors":"Ming-Chien Chen, Ying-Hsu Chang, Ting-Wen Sheng, Liang-Kang Huang, Hung-Chen Kan, Chung-Yi Liu, Po-Hung Lin, Kai-Jie Yu, Cheng-Keng Chuang, See-Tong Pang, Chun-Te Wu, I-Hung Shao","doi":"10.2147/TCRM.S472180","DOIUrl":"10.2147/TCRM.S472180","url":null,"abstract":"<p><strong>Background: </strong>Evaluating risk factors for bleeding events in robot-assisted partial nephrectomy (RAPN) for renal angiomyolipoma (RAML) is essential for improving surgical outcomes.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients who underwent RAPN for renal masses between May 2019 and June 2023 at a single medical center, categorizing them into AML and non-AML groups. We assessed demographic data, perioperative complications, and postoperative outcomes. Preoperative imaging was reviewed to calculate R.E.N.A.L and PADUA nephrometry scores. Receiver operating characteristic (ROC) curve analysis was used to evaluate the accuracy of risk factors related to estimated blood loss (EBL) and blood transfusion.</p><p><strong>Results: </strong>Among 255 patients, 71 (27.8%) had AML, and 184 (72.2%) had non-AML. The average age was 54.5 years, with 80.2% of the AML group being female. The median tumor size was 50.2 mm. The AML group had larger tumor diameters (50.2 mm vs 34.9 mm) but shallower depths (16.1 mm vs 21.7 mm). Median R.E.N.A.L and PADUA scores were 6.5 and 8.2, respectively, with a median EBL of 128.2 mL. Blood transfusion was required in 15.5% of cases. Tumor diameter, depth, R.E.N.A.L score, and PADUA score significantly correlated with EBL, while BMI, tumor diameter, and R.E.N.A.L score correlated with blood transfusion. The AUCs for predicting EBL and blood transfusion were 0.778 and 0.771 for tumor diameter, and 0.661 and 0.711 for R.E.N.A.L score.</p><p><strong>Conclusion: </strong>RAPN might be a safe option for RAML, with tumor diameter being the most accurate predictor of EBL and blood transfusion. These findings can improve preoperative assessments and surgical planning.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"883-892"},"PeriodicalIF":2.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Endonasal Surgery of Skull Base Osteoradionecrosis with the Internal Carotid Artery Invaded: Clinical Characteristic and Surgical Strategy.","authors":"Tianfeng Zhao, Zhuo Xu, Min Xu, Yubin Lai, Xiaodong Chen, Zhaohui Shi","doi":"10.2147/TCRM.S479849","DOIUrl":"10.2147/TCRM.S479849","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to summarize the clinical characteristics of skull base osteoradionecrosis (ORN) with the internal carotid artery (ICA) involvement and to distill the key surgical techniques that can enhance the protective measures for ICA.</p><p><strong>Methods: </strong>We conducted a retrospective, observational study over a six-year period from February 2017 to May 2023. We included patients who were diagnosed with osteoradionecrosis with invasion of the internal carotid artery and collected their demographic information, pathology results, complication rates, ect. The goal was the alleviated rate after the surgery and the anatomic consideration during the surgery. We compared the verbal rating score (VRS) of headache pre- and post-operation by the Wilcoxon rank-sum test.</p><p><strong>Results: </strong>A retrospective analysis was conducted on 19 patients diagnosed with ORN, with a mean age of 53.73 yr (range, 32-68 yr). Among them, 17 patients (89.47%) were nasopharyngeal carcinoma (NPC), 1 patient (5.23%) was squamous cell carcinoma of the sphenoid sinus, and 1 patient (5.23%) had adenoid cystic carcinoma. After the surgery, 1 fatality occurred within 2 months, which was attributed to a severe parapharyngeal space infection.1 patient succumbed to ICA rupture two days post-operation. Additionally, 1 patient experienced ORN recurrence 2 years after the initial surgery. The mean follow-up period for the study was 37.47 mo (range 2 -77 mo). The alleviation rate was 89.4%. The results revealed a significant decrease in VRS after the surgery (Z=-3.921, P=0.000). Finally, we summarized clinical evidences of ICA involvement, such as the formation of pseudoaneurysm.</p><p><strong>Conclusion: </strong>A four-quadrant division of SBORN as a standardized and systematic approach is meaningful to guide surgical intervention for osteoradionecrosis. There are relevant clinical and imaging evidences that can predict the rupture of ICA.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"871-881"},"PeriodicalIF":2.8,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Levosimendan on Low Cardiac Output Syndrome After Pericardiectomy.","authors":"Likui Fang, Pengfei Zhu, Guocan Yu, Wang Lv, Jian Hu","doi":"10.2147/TCRM.S496574","DOIUrl":"10.2147/TCRM.S496574","url":null,"abstract":"<p><strong>Background: </strong>Low cardiac output syndrome (LCOS) after pericardiectomy is associated with high morbidity and mortality. This study aimed to assess the effect of levosimendan on postoperative LCOS in the patients with constrictive pericarditis.</p><p><strong>Methods: </strong>Patients were retrospectively enrolled, and those receiving the treatment of levosimendan were assigned in the LEVO (+) group, and others were in the LEVO (-) group. Postoperative outcomes including durations of intubation, vasoactive agents using, ICU stay, hospital stay and mortality were compared between the two groups.</p><p><strong>Results: </strong>A total of 32 patients were eligible for analysis, 19 of whom were in the LEVO (+) group, and 13 of whom were in the LEVO (-) group. The LEVO (+) group was associated with shorter postoperative duration of intubation (P < 0.001), vasopressor using (P = 0.006), ICU stay (P = 0.001) and hospital stay (P = 0.042), and less incidence of acute liver or kidney injury (P = 0.046). There were no significant differences in 30-day mortality and 1-year mortality between the LEVO (+) group and the LEVO (-) group. The prevalence of adverse events in the LEVO (+) group was acceptable.</p><p><strong>Conclusion: </strong>Levosimendan could be administered in the patients with constrictive pericarditis developing LCOS after pericardiectomy to enhanced postoperative recovery.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"861-869"},"PeriodicalIF":2.8,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety Profile of Balanced Propofol Sedation for Bronchoscopy.","authors":"Xinyu Wu, Lina Zhang, Zangong Zhou, Lijie Qi, Yinhuan Liu, Xuebin Du, Lixia Ma, Xiangyu Ji","doi":"10.2147/TCRM.S495253","DOIUrl":"10.2147/TCRM.S495253","url":null,"abstract":"<p><strong>Purpose: </strong>We conducted a prospective, real-world study to evaluate the efficacy and safety of balanced propofol sedation (BPS) in bronchoscopy and identify an advantageous sedation regimen for such procedures.</p><p><strong>Patients and methods: </strong>The participants were placed in four groups based on their sedation regimen (exposure factor): the M-S group (midazolam + sufentanil for traditional sedation), R-S group (remimazolam + sufentanil for traditional sedation), M-S-P group (midazolam + sufentanil + propofol for BPS), and R-S-P group (remimazolam + sufentanil + propofol for BPS). The primary outcomes included satisfaction metrics (satisfaction of the patients, endoscopic physicians, and nurses) and follow-up questionnaires. The secondary outcomes included time metrics (induction time, recovery time, and discharge time), dosage metrics (induction dose, maintenance dose, and total dose of each sedative), completion rate of sedation, intraprocedural dose, and frequency of lidocaine spray in the airway, and incidence of adverse reactions.</p><p><strong>Results: </strong>In total, 418 subjects were included in this study. Compared to traditional sedation, both BPS groups significantly increased the satisfaction of patients, endoscopic physicians, and nurses (P < 0.05) and reduced the incidence of intraprocedural wakefulness (P < 0.05). Additionally, induction and recovery of the BPS group were rapid, with high sedation completion rates and no increase in the incidence of intraprocedural and postprocedural adverse reactions (P < 0.05). The RSP group was better than the MSP group in terms of various time metrics and postprocedural adverse reactions.</p><p><strong>Conclusion: </strong>BPS can be safely and effectively applied during bronchoscopy, with remimazolam and sufentanil combined with a small dose of propofol being an optimal medication regimen.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"849-860"},"PeriodicalIF":2.8,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Effect of a New Surgical Medical Drain Anti-Dislodgement Fixation Patch and Fixation Method in Postoperative Thyroid Care: A Randomized Trial.","authors":"Caizhen Zhang, Weiping Mi, Yajun Zhu, Yonghao Li, Yifan Cao, Zhensu Li","doi":"10.2147/TCRM.S491307","DOIUrl":"10.2147/TCRM.S491307","url":null,"abstract":"<p><strong>Participants: </strong>This study enrolled 294 patients admitted to the Thyroid Surgery Department of the First Hospital of Shanxi Medical University between April and July 2024. Patients were randomly assigned to either the control group (145 patients) or the experimental group (149 patients).</p><p><strong>Interventions: </strong>The control group received traditional adhesive tape fixation for drains, while the experimental group utilized a newly developed fixation patch combined with a unique \"C\" and \"S\" fixation method. Both groups employed vertical negative pressure drainage.</p><p><strong>Specific objectives or hypotheses: </strong>The aim of this study was to assess the clinical effectiveness and patient satisfaction with a novel surgical drain fixation patch and method in the context of thyroid surgery. The hypothesis was that the novel fixation patch and method would reduce drain-related adverse events, improve patient comfort, and increase patient satisfaction.</p><p><strong>Outcomes: </strong>The experimental group exhibited significantly lower rates of drain-related adverse events, including displacement, infection, and leakage, compared to the control group (3.40% vs 53.10%, P < 0.05). Additionally, patients in the experimental group reported lower neck/throat pain scores (mean score: 0.84 vs 1.40 in the control group, P < 0.05) and experienced no drain pulling pain (0% vs 1.16% in the control group, P < 0.05). Furthermore, the need for patch replacements was virtually eliminated in the experimental group (0% vs 70.86% in the control group, P < 0.05). Patient satisfaction with the fixation method was significantly higher in the experimental group (83.3% vs 46.9% in the control group, P < 0.05).</p><p><strong>Randomization: </strong>Patients were randomly assigned to the control and experimental groups, ensuring the fairness and reliability of the study.</p><p><strong>Trial registration: </strong>The study was retrospectively registered with the China Clinical Trial Registry (ChiCTR2400087677) on August 1, 2024.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"837-847"},"PeriodicalIF":2.8,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11640031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment with Esketamine Reduces Etomidate-Induced Myoclonus During the Induction of Anesthesia: A Randomized Controlled Trial.","authors":"Jiang Wang, Mengmeng Zhu, Yuanyuan Cao, Lei Zhang, Lijian Chen","doi":"10.2147/TCRM.S485626","DOIUrl":"10.2147/TCRM.S485626","url":null,"abstract":"<p><strong>Background: </strong>Myoclonus is a common problem during induction of anesthesia with etomidate. A variety of agents, including opioids and lidocaine, reduced the incidence of myoclonus. However, there is no reported literature evaluating the effect of esketamine pretreatment on etomidate-induced myoclonus. We investigated the influence of pretreatment with esketamine on the incidence of etomidate-induced myoclonus.</p><p><strong>Methods: </strong>This is a prospective, double-blind, and randomized controlled trial. One hundred patients aged 18-65 scheduled for elective surgery under general anesthesia (including urology surgery, gynaecology surgery, general surgery, and thoracic surgery) were randomly allocated into two groups, each consisting of 50 patients. Esketamine was pretreated with 0.1 mg/kg 60 s before the initiation of etomidate in Group ESK, while normal saline was administered as the placebo (Group C). During the first 1 minute after etomidate administration, myoclonus incidence and severity were assessed. In addition, we measured the hemodynamic changes and side effects of esketamine before administering etomidate.</p><p><strong>Results: </strong>In group ESK, 14 patients (28%) had myoclonus (degrees of myoclonus: mild 2, moderate 7, severe 5), and 32 patients (64%) in group C (mild 6, moderate 5, severe 21) (<i>P</i>< 0.001). In group ESK, myoclonus incidence and severity were significantly lower than in group C (<i>P</i>< 0.001).</p><p><strong>Conclusion: </strong>Esketamine 0.1mg/kg IV pretreatment significantly reduce the incidence and the severity of severe myoclonus of etomidate-induced myoclonus without significant adverse effects.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"829-836"},"PeriodicalIF":2.8,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial Fibrillation Types and Chronic Kidney Disease are Independent Predictors of Atrial Fibrillation Recurrence After Radiofrequency Ablation.","authors":"Pei Mo, Cheng Fan, Jiayuan Chen, Yu Wang, Wenhao Xiao, Zhiguo Peng, Xiao-Zhen Lin, Cheng-Feng Luo, Chongyu Zhang","doi":"10.2147/TCRM.S492265","DOIUrl":"10.2147/TCRM.S492265","url":null,"abstract":"<p><strong>Purpose: </strong>Atrial fibrillation (AF) is classified into paroxysmal, persistent, long-term persistent, and permanent types. It is commonly treated by radiofrequency ablation (RFA), which is more successful than conventional anti-arrhythmic drugs, but it is still largely unknown whether these beneficial effects are equally present for all AF types. Here, we evaluated the impact that AF type has on post-RFA patient conditions and identified underlying factors affecting AF prognoses.</p><p><strong>Patients and methods: </strong>Three hundred and twenty-nine AF patients who underwent RFA were retrospectively examined (221 paroxysmal, 56 persistent, 52 long-term persistent), during a post-RFA follow-up period, from 3-months to 2-years. Cardiac functional parameters, such as left atrial (LA), ventricular (LV), and pulmonary artery diameters, as well as ejection fraction (EF) and end-diastolic/systolic diameter ratio, were measured using echocardiography. Additionally, chronic kidney disease (CKD) was diagnosed among these AF patients, using the Modification of Diet in Renal Disease (MDRD) formula, and its impact on post-RFA patient outcomes was examined. Logistic regression analysis identified differences between AF and non-AF recurrence groups.</p><p><strong>Results: </strong>In terms of functional parameters, persistent AF had significantly smaller LA, and larger EF, compared to paroxysmal and long-term persistent groups, while paroxysmal had significantly larger LV versus persistent and long-term persistent after RFA. For post-RFA patient conditions, paroxysmal, compared to persistent and long-term persistent, had significantly lower AF recurrence (18.10% versus 30.36% and 36.54%) and re-hospitalization rates (6.79% versus 14.29% and 19.23%); however, no significant difference was present between the 3 groups in terms of post-operative stroke rates, as well as re-hospitalization duration. Additionally, CKD patients, versus non-CKD, were more prone to AF recurrence and re-hospitalization, being 3.268 times more likely.</p><p><strong>Conclusion: </strong>AF types and CKD were independent factors influencing AF recurrence, serving as highly sensitive predictors to monitor prognoses and guide treatments. Therefore, personalized treatment regimens should be recommended for different AF patients.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"817-828"},"PeriodicalIF":2.8,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the High-Intensity Focused Electromagnetic Energy an Effective Treatment for Urinary Incontinence in Women?","authors":"Halil Tosun, Emre Can Akınsal, Gökhan Sönmez, Numan Baydilli, Deniz Demirci","doi":"10.2147/TCRM.S478919","DOIUrl":"10.2147/TCRM.S478919","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the effectiveness and safety of high-intensity focused electromagnetic technology (HIFEM) used as a therapeutic approach in patients with stress and mixed urinary incontinence.</p><p><strong>Patients and methods: </strong>Thirty-five females suffering from stress and mixed urinary incontinence were included in the study. The electromagnetic chair (BTL EMSELLA^®) was applied to the patient's pelvic area twice a week for 28 minutes, totaling 6 sessions. The patients' \"International Consultation on Incontinence Questionnaire-Short Form\" (ICIQ-SF) scores and the number of daily absorbent pad usage were recorded. Results were evaluated after the sixth session and at a first-month follow-up.</p><p><strong>Results: </strong>The average ICIQ-SF score at baseline was 10.18 ± 4.19 (ranging from 2-18) which declined to 5.33 ± 3.97 after six sessions, and further improved to 4.26 ± 3.94 points at the one-month follow-up. After six sessions, an average improvement of 52.06% in ICIQ-SF score was observed, and after one month of follow-up, an average improvement of 59.6% was detected, which was found to be statistically significant (p=0.038). In addition, the mean number of pads used per day decreased to 1.25 ± 1.54 after treatment, a significant improvement was observed, and the mean daily pad use decreased further to 0.91 ± 1.11 at the first-month follow-up.</p><p><strong>Conclusion: </strong>HIFEM has demonstrated in our study its ability to safely and effectively treat female patients suffering from stress and mixed urinary incontinence, as evidenced by significant improvements in symptoms and quality of life observed in clinical trials.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"811-816"},"PeriodicalIF":2.8,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe β-Thalassemia Patients.","authors":"Wei-Jia Yang, Lian-Dong Shi, Ye Liang, Li-Ming Liang, Hao Zhang, Li Wang, Qian Zhou","doi":"10.2147/TCRM.S481128","DOIUrl":"10.2147/TCRM.S481128","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we evaluated the effectiveness and safety of thalidomide by clinically observing 48 individuals with β-thalassemia who have been administered thalidomide in small and medium doses over a period of two years.</p><p><strong>Methods: </strong>Thalidomide's efficacy was gauged by tracking hemoglobin (Hb) level alterations post its administration. Liver and kidney function impact was measured through tests for alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine. Hemolysis effects were assessed via total bilirubin and indirect bilirubin level measurements. Thrombosis detection was performed using ultrasound examinations of deep vein vessels in the upper and lower extremities. Any adverse effects of thalidomide were recorded during the observation period. Lower dose thalidomide effectiveness was evaluated by monitoring Hb level changes following dosage reduction.</p><p><strong>Results: </strong>The overall response rate (ORR) among the 48 participants was 91.7% (44 out of 48), with the main reaction (MaR) reaching 72.9% (35 out of 48). Hepatorenal toxicity was not monitored during the 2-year observation period, and there was no improvement in hemolysis. Most adverse effects were mild, with no instances of venous thrombosis and no cases of grade 2 or higher neurotoxicity. When the observation group was divided into three age categories (12-14 years old, 14-18 years old, and over 18 years old), there were no statistically significant differences in the occurrence of adverse reactions among the three groups. As there were some adverse reactions in ten cases, the treatment dose was reduced for them. The maintenance efficacy rate at one year of observation was 90% (9 out of 10).</p><p><strong>Conclusion: </strong>This study confirmed that thalidomide in small doses over a 2-year observation period is effective, and has no instances of grade 2 or higher neurotoxicity. Long-term maintenance with small doses is recommended for enhanced safety.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"799-809"},"PeriodicalIF":2.8,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}